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The recent RAF inhibitor trial with PLX4032/RG7204 in
late-stage mutant B-RAF melanoma patients has been
lauded as a success story for personalized cancer
therapy since short-term clinical responses were
observed in the majority of patients. However, initial
responses were followed by subsequent tumor re-
growth, and a subset of patients showed intrinsic
resistance. Bi-directional translational efforts are now
essential to determine the mechanisms underlying
acquired/secondary and intrinsic resistance to RAF
inhibitors.
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INTRODUCTION
Metastatic dissemination of melanoma occurs to multiple
sites, and is associated with 2–16% 10-year survival
expectancy depending on the site of metastasis. Melanoma
is a paradigm for chemoresistance and treatment options
have remained limited for decades. Standard chemotherapy,
such as the alkylating agent and dacarbazine, elicits a
response rate of only 10% (Flaherty, 2010). Immunotherapy
options, such as high-dose IL 2 and anti-CTLA4 (ipilimumab),
have shown improved median survival benefits, but again
response rates are low and the side effects of these treatments
can be severe. Recently, targeted therapies have been
designed to selectively kill melanoma cells harboring
mutations in the serine–threonine kinase, B-RAF. Approxi-
mately, 50–60% of melanomas harbor B-RAF mutations
(Davies et al., 2002); the most frequent mutation is a valine
to glutamic acid substitution at codon 600 (V600E). V600E,
as well as V600K/D mutations, lead to constitutive B-RAF
kinase activity and elevate downstream signaling through
the MEK (mitogen-activated protein kinase/extracellular
signal-regulated kinase)–ERK1/2 (extracellular signal-regu-
lated kinase 1/2) pathway. B-RAFV600E is a driver mutation
that promotes melanoma growth and survival in a variety of
pre-clinical models and inhibiting B-RAF expression/activity
results in growth inhibition and cell death (Dhomen and
Marais, 2007). However, B-RAFV600E mutations are also
found in benign nevi and, hence, are not sufficient for
malignancy.
PLX4032/RG7204 was recently developed as a potent
adenosine triphosphate-competitive inhibitor of RAFs, with
modest preference in vitro for mutant B-RAF and C-RAF
compared with wild-type B-RAF (Bollag et al., 2010).
However, in cells it functions as a selective inhibitor
of mutant B-RAF signaling (Bollag et al., 2010), probably
because of the higher adenosine triphosphate Km(app) for
B-RAFV600E in mM cellular concentrations of adenosine
triphosphate compared with wild-type forms of B-RAF and
C-RAF (Hatzivassiliou et al., 2010). In a phase 1 trial, 81% of
melanoma patients harboring B-RAFV600E showed objective
tumor regression by RECIST criteria following PLX4032
treatment (Flaherty et al., 2010). In addition, a second
adenosine triphosphate-competitive RAF inhibitor,
GSK2118436, is showing promising results in phase 1 trials
with a 63% response rate observed in mutant B-RAFV600E/K/D
patients (Kefford et al., 2010). However, in the PLX4032 trial,
the clinical effects were temporary and the length of tumor-
free survival averaged 7 months (Smalley and Sondak, 2010).
Furthermore, 19% of patients in the phase 1 trial did not show
tumor regression 430% (Flaherty et al., 2010). Thus,
acquired and intrinsic modes of resistance are hampering
the clinical efficacy of PLX4032. It is critical to understand
the mechanisms of resistance in order to optimize PLX4032
activity and improve the response rates, as well as the
duration of clinical benefit. Emerging evidence from patient-
matched pre-treatment and post-relapse samples (Table 1)
highlights that multiple mechanisms underlie resistance to
PLX4032 and likely other RAF inhibitors (Figure 1). These
mechanisms can be divided into four non-mutually exclusive
categories: re-activation of RAF–MEK signaling, alterations in
ERK1/2-regulated cell cycle events, activation of alternative
signaling pathways, and chromatin-regulating events.
RE-ACTIVATION OF THE RAF–MEK SIGNALING
PATHWAY
The most direct route for a melanoma cell to by-pass RAF
inhibitor action is by re-activation of the RAF–MEK–ERK1/2
pathway. Indeed, enhanced phosphoERK1/2 levels have been
observed in mutant B-RAF melanoma cell lines that have
acquired resistance to RAF inhibitors (PLX4032 and its non-
clinical tool compound PLX4720, AZ628, and SB-590885)
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through continued culture in the presence of drug (Montagut
et al., 2008; Paraiso et al., 2010; Tap et al., 2010; Villanueva
et al., 2010). A notable difference (at least to date) from
resistance mechanisms to Abl kinase and EGFR inhibitors in
chronic myelogenous leukemia and non-small cell lung
cancer, respectively, is the lack of secondary gatekeeper
mutations in the drug target. Although mutation of the
gatekeeper amino acid, threonine 529, renders B-RAFV600E
resistant to PLX4720 in cell-based assays (Whittaker et al.,
2010), deep-sequencing analysis indicates that threonine 529
or other sites in B-RAF are not mutated in resistant tumor
samples and cell lines (Nazarian et al., 2010; Tap et al.,
2010). Rather upregulation/amplification of other mitogen-
activated protein kinase kinase kinases (MAP3Ks) seems
to be a more prominent mechanism. C-RAF and A-RAF are
paralogs of B-RAF. Settleman and colleagues showed that
elevated C-RAF expression was associated with mutant
B-RAF melanoma cell resistance to AZ628 (Montagut et al.,
2008). Depletion of C-RAF from melanoma cells with
acquired resistance to AZ628 enhanced susceptibility to
RAF inhibition. Conversely, C-RAF overexpression in parental
cells enhanced resistance to AZ628 (Montagut et al., 2008).
AZ628-resistant cells showed enhanced susceptibility to
geldanamycin, an agent that reduces RAF protein levels
by targeting its chaperone protein, heat shock protein 90
(Montagut et al., 2008). A modest increase in C-RAF
expression was also observed in melanoma cells acquiring
resistance to SB-590885 (Villanueva et al., 2010). In these
studies, the authors propose that RAF isoform switching
mediates the maintenance of elevated ERK1/2 phosphoryla-
tion. This notion is based on the requirement for molecular
depletion of A-RAF and C-RAF, as well as SB-590885 (which
is more potent against B-RAF compared with A- or C-RAF) to
completely inhibit ERK1/2 phosphorylation in SB-590885-
acquired resistant cells (Villanueva et al., 2010). However, it
should be noted that maintenance of phosphoERK1/2 levels
in these studies co-occurs with acquisition of alternative
resistance pathways (see below).
Further support for a role for C-RAF in resistance to B-RAF
inhibition was provided by Garraway and colleagues using a
complementary DNA screen for kinases that prevent
PLX4720-mediated cell growth arrest (Johannessen et al.,
2010). This screen also identified a non-RAF MAP3K, Cot1/
Tpl2/MAP3K8. Cot1 activated MEK-ERK1/2 signaling in
PLX4720-treated mutant B-RAF cell lines and cell lines
endogenously expressing elevated levels of Cot1 were
intrinsically resistance to PLX4720 (Johannessen et al.,
2010). Importantly, Cot1 mRNA levels were increased in
Table 1. Evidence from patient-matched pre-treatment and post-relapse samples
Gene Alteration(s) in patient samples Reference
Cot1 Enhanced Cot1 mRNA levels following PLX4032 treatment in two out of three patient samples analyzed Johannessen et al. (2010)
IGF-1R Enhanced IGF-1R staining in relapse samples in two out of five patients compared with pre-treatment samples Villanueva et al. (2010)
N-RAS Two out of 16 relapse samples harbored acquired N-RAS mutations. The two tumors were independent
metastases from the same patient.
Nazarian et al. (2010)
PDGFRb Four out of 11 PLX4032-resistant tumor samples showed elevated PDGFRb staining compared with
patient-matched samples from the pre-treatment condition.
Nazarian et al. (2010)
Abbreviations: IGF-1R, IGF-1 receptor; PDGFRb, platelet-derived growth factor receptor b.
PDGFRβ
PI3K B-RAF
C-RAF C-RAF
MEK
ERK
Cot1
i
ProliferationSurvival
Bim-EL and Bmf
PTEN
RTKIGF-1R
Mcl-1
Cyclin D1
p27Kip1
i V600E
AKT3
?
C121S
P124L
RAS RASQ61R/K
Figure 1. Multiple mechanisms of resistance to RAF inhibitors in mutant
B-RAF cells. Resistance to RAF inhibitor (i) blockade of signaling through the
MEK–ERK1/2 pathway can occur via acquired mutation in N-RAS (Q61K or
Q61R) or upregulation of RTK. These mechanisms enhance RAS activity,
which promotes C-RAF dimerization and activation. MEK–ERK1/2 pathway
activation can also occur through mutations in the B-RAF target, MEK1
(P124L), and via upregulation of the MAP3K and Cot1. Activation of the
parallel PI-3 kinase–Akt pathway is promoted by loss of PTEN expression/
activity, often through mutation and upregulation of RTKs including IGF-1R
and possibly PDGFRb. Re-activation of the ERK1/2 pathway and PI-3K–Akt
signaling promote G1/S cell cycle events including cyclin D1 upregulation
and downregulation of the cyclin-dependent inhibitor, p27Kip1. In addition,
these pathways promote survival events by promoting expression of the anti-
apoptotic protein, Mcl-1, as well as down-modulating levels of the pro-
apoptotic BH3-only proteins, Bim-EL, and Bmf. Alterations in the expression
of these cell cycle and survival proteins may also promote resistance to RAF
inhibitors. ERK, extracellular signal-regulated kinase; IGF-1R, IGF-1 receptor;
MAP3K, mitogen-activated protein kinase kinase kinase; MEK, mitogen-
activated protein kinase/extracellular signal-regulated kinase; PDGFRb,
platelet-derived growth factor receptor b; PI-3K, phosphatidylinositol 3
kinase; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine
kinase.
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two out of three relapsed tumors samples analyzed from
PLX4032-treated patients, indicating relevance to the in vivo
situation (Johannessen et al., 2010). B-RAF inhibition in cell
lines led to increased Cot1 levels, raising the possibility that
Cot1 upregulation is an adaptive response to PLX4032.
However, RAF inhibitor-induced Cot1 upregulation in cells
was independent of mRNA alterations, indicating a distinct
mechanism to the Cot1 upregulation observed in patients.
The above studies highlight that compensatory upregula-
tion of MAP3Ks, such as Cot1, is likely to represent one
mechanism of resistance to RAF inhibitors in patients.
However, mechanisms upstream of MAP3Ks also appear
likely in a subset of resistant tumors. Upstream of RAFs are
the RAS guanosine triphosphatases that recruit RAFs to the
membrane for activation. N-RAS is mutated in B15% of
melanomas in a manner that is mutually exclusive from
B-RAF mutation. The potential role of RAS in altering the
effects of RAF inhibitors was highlighted by a series of papers
showing that RAF inhibitors lead to a paradoxical hyper-
activation of MEK–ERK1/2 signaling in cells harboring mutant
N-RAS/high RAS activity (reviewed in Kaplan et al. (2010).
Indeed, ectopic expression of mutant N-RAS in a mutant
B-RAF colorectal cancer cell line nullifies the inhibitory
effects of PLX4720 (Poulikakos et al., 2010), a result that is
reproducible in B-RAFV600E melanoma cells (Johannessen
et al., 2010; Nazarian et al., 2010). Knockdown of mutant
N-RAS reverses the insensitivity of PLX4032-resistant cell
lines and, importantly, N-RAS mutations were detected in
two independent progressing tumors from a PLX4032-treated
patient (Nazarian et al., 2010). Elevated RAS activity in the
absence of RAS mutations was detected in cell lines with
acquired resistance to PLX4032 indicating that events that
promote elevated RAS signaling will likely elicit similar
effects. Thus, the co-occurrence of B-RAF mutations and RAS
mutation/activation is likely to promote resistance to
PLX4032 and other RAF inhibitors.
Another possible mechanism to by-pass the activity of RAF
inhibitors is through alterations in B-RAF effectors. MEK1 and
2 are phosphorylated and activated by B-RAF and a P124L
mutation in MEK1 was identified through a MEK1 random
mutagenesis screen that confers cellular resistance to the
MEK inhibitor, AZD6244 (Emery et al., 2009). MEK1P124L
expression conferred resistance to PLX4720 in cell-based
assays and was identified in a metastasis from a patient with
acquired resistance to AZD6244, indicating the clinical
relevance of this mutation. Interestingly, the combination of
PLX4720 plus AZD6244 overcame the resistance conferred
by MEK1P124L expression. These and other data have
prompted the use of MEK inhibitors in clinical trials enrolling
mutant B-RAF melanoma patients who were previously
treated with or without a BRAF inhibitor.
ALTERATIONS IN ERK1/2-REGULATED CELL CYCLE
EVENTS
Mutant B-RAF signaling via ERK1/2 promotes G1/S cell cycle
progression, at least in part, through control of cyclin D1
levels, which enhance cyclin-dependent kinase activity to
promote hyperphosphorylation of retinoblastoma (Bhatt
et al., 2005). Studies using retinoblastoma-null fibroblasts
and tumor lines have demonstrated the requirement of an
intact cyclin–cyclin-dependent kinase–retinoblastoma axis for
MEK inhibitor prevention of cell cycle entry (D’Abaco et al.,
2002). Approximately, 25% of mutant B-RAF melanoma cell
lines and tumor samples harbor amplifications in cyclin D1
(Smalley et al., 2008). Furthermore, overexpression of cyclin-
dependent kinase 4 and cyclin D1 in a SB-590885-sensitive
cell line promotes resistance to this RAF inhibitor (Smalley
et al., 2008). An implication of this work is that mutant B-RAF
patients with amplification of the cyclin D1 locus or other
alteration on the cyclin–cyclin-dependent kinase–retinoblas-
toma axis will likely be intrinsically resistant to PLX4032 and,
thus, patients stratified on this basis may be predictive of the
response.
ACTIVATION OF ALTERNATIVE SIGNALING PATHWAYS
Multiple laboratories have generated mutant B-RAF cell lines
that have acquired resistance to RAF inhibitors but not all of
these lines show re-activation of the ERK1/2 pathway
(Montagut et al., 2008). These findings indicate that input
from alternative, ERK1/2-independent pathways induce RAF
inhibitor resistance mechanisms. In the Garraway screen,
protein kinase C-e, protein kinase C-Z, and ErbB2 individu-
ally provided resistance to PLX4720 in the absence of ERK1/2
re-activation (Johannessen et al., 2010). Studies from
Nazarian et al. (2010) implicate the platelet-derived growth
factor receptor b (PDGFRb) receptor tyrosine kinase in the
resistance to PLX4032. PDGFRb is upregulated in PLX4032-
resistant patient biopsies. Furthermore, resistant cell lines
with upregulated PDGFRb were dependent on PDGFRb
for proliferation and survival despite PLX4032 inhibition
of the ERK pathway remained intact. Consistent with an
ERK1/2-independent resistance mechanism, the growth of
PDGFRb-overexpressing resistant cells was insensitive to
MEK inhibitors. However, the mechanism underlying
PDGFRb-mediated resistance to PLX4032 is currently unclear.
Other studies implicate the phosphatidylinositol 3 kina-
se–Akt signaling pathway in resistance to RAF inhibitors.
Elevated Akt activity was detected in two out of three cell
lines with acquired resistance to PLX4032 (Tap et al., 2010).
In addition, enhanced Akt phosphorylation is acquired and
associated with increased expression of IGF-1 receptor or
depletion of phosphatase and tensin homolog in relapsed
tumor samples from PLX4032-treated patients (Villanueva
et al., 2010). Consistent with activation of the Akt pathway
providing resistance to RAF inhibitors, expression of con-
stitutively active Akt3 inhibited PLX4720-induced apoptosis
in three-dimension by preventing upregulation of the pro-
apoptotic BH3-only protein, Bim-EL, and Bmf, following
B-RAF inhibition (Shao and Aplin, 2010). Notably, MEK
inhibitors in combination with either an IGF-1 receptor
inhibitor or a phosphatidylinositol-3 kinase inhibitor induces
cell death in RAF inhibitor acquired resistant cell populations
(Villanueva et al., 2010). Importantly, these data have
provided new strategies to overcome resistance to RAF
inhibitors and the combination of MEK and Akt inhibitors is
being pursued in clinical trials.
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CHROMATIN-REGULATING EVENTS
Acquired mutations are rare events and time is required for
the resistant cells to outgrow from the tumor mass. To
account for the ability of cells to withstand drug toxicity in
the short term, it has been proposed that reversible ‘‘drug-
tolerant’’ states exist before the acquisition of permanent
resistance (Sharma et al., 2010). Tolerance is drug-induced
suggesting an adaptive response to targeted therapies. In
addition, tolerance is reversible and a fraction of tolerant cells
revert to a sensitive state during a ‘‘drug holiday’’. Thus, a
second round of drug treatment will promote tumor cell
death and the cycle will repeat until secondary mutations
lead to permanent resistance. When challenging tumor cell
lines with various anticancer agents, Settleman and collea-
gues detected sub-populations of tumor cell lines that show
higher (4100-fold) drug tolerance than the remainder of the
cells (Sharma et al., 2010). This reversible drug-tolerant state
is transiently acquired through elevated IGF-1 receptor
signaling and chromatin remodeling mediated by enhanced
expression of JARID1A, a histone demethylase (Sharma et al.,
2010). JARID1A associates with histone deacetylases
and treatment of M14 melanoma cells with inhibitors of
either IGF-1 receptor or histone deacetylases in combination
with the RAF inhibitor, AZ628, prevents the emergence
of AZ628-tolerant cells. Melanoma cells are known
for their plasticity, and these studies indicate that an
adaptive chromatin regulation response to targeted
therapies may contribute ultimately to the acquisition of a
resistant state.
CONCLUDING REMARKS
There is a clear need to build on the initial success of the
PLX4032 trial in melanoma. As an increasing number of
patient-matched pre-treatment, during treatment and post-
treatment samples become available, state-of-the-art genomic
and proteomic approaches need to be used to reveal the
prominence of the mechanisms described above and reveal
to our knowledge, previously unreported ways to promote
resistance to RAF inhibitors. The findings are translational
and will drive the specification of next generation RAF
inhibitors and combinational strategies to provide lasting
treatment to melanoma sufferers.
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NOTE ADDED IN PROOF: Further emphasizing re-activation of the ERK1/2
pathway as a mechanism of resistance to PLX4032, Garraway and colleagues
recently identified an acquired MEK1 mutation (C121S) in one patient who
relapsed on a PLX4032 trial (Wagle et al., 2011). Expression of MEK1-C121S
in mutant B-RAF melanoma cells conferred resistance to both RAF and
allosteric MEK inhibitors, suggesting that molecular intervention downstream
of MEK activation may be required in some patients with acquired resistance
to RAF inhibitors.
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